164 results
Page 3 of 9
424B5
sg9qypw
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
vklcwo5e3rlgbxy
6 May 22
Regulation FD Disclosure
2:50pm
8-K
EX-99.1
cg8440730ysderua
28 Apr 22
Regulation FD Disclosure
2:35pm
424B3
s3gm0a6
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-10.1
q5kmatb
7 Apr 22
Entry into a Material Definitive Agreement
4:47pm
424B3
xb4sofxa 4sg0
7 Apr 22
Prospectus supplement
4:46pm
8-K
EX-10.1
kmjuif3136g8y
22 Mar 22
Entry into a Material Definitive Agreement
6:05am
S-3
b8mldn5omswuk0 voxqo
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
s2t33 l58z1k9yzq
19 Jan 22
InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
4:09pm
8-K
EX-99.1
sduen74 o6k9
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
8-K/A
EX-99.2
tyi7qipzeokjzxp
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.3
84x2da
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.1
3z7nvyw7mu0
22 Dec 21
Audited Financial Statements
12:00am
DEF 14A
6xezcz b6t2bh
28 Oct 21
Definitive proxy
3:07pm
8-K
EX-2.1
pfmkt2qosf
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm